- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04982692
A Clinical Study of Intravaginal Prasterone (Intrarosa®) in Postmenopausal Vulvovaginal Atrophy
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase Ⅲ, Efficacy and Safety Study of Intravaginal Prasterone (INTRAROSA) on Postmenopausal Vulvovaginal Atrophy (VVA)
This study is a phase III which includes two treatment phases. The phase 1 study is a multi-center, randomized, double-blind, placebo- controlled, parallel group that provide primary efficacy and safety data.
The Phase 2 study is a single-arm, open-label conducted in a subset of subjects who completed the phase 1 study to provid additional long-term safety and efficacy.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The phase 1 study which includes the screening phase (up to 3 weeks) and treatment phase (12 weeks). After signing the informed consent, the inclusion and exclusion criteria will be confirmed preliminarily at screening visit and reconfirmed at Day 1 (baseline). At least 418 eligible subjects will be randomized in a 1:1 ratio to receive 6.5mg of intravaginal prasterone or placebo once-daily for 12 weeks.
The phase 2 study which includes the treatment phase (26 weeks). A total of 100 subjects who have completed Phase 1, not occur adverse event(AE) grade ≥3 or serious adverse event (SAE), or recover all AE grades ≤1, and voluntary to participate in Phase 2 study. After signing the ICF, the subject will receive 6.5mg of intravaginal for 26 weeks.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Shanghai, China
- Obstetrics and Gynecology Hospital of Fudan University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject is between 40 and 80 years of age inclusive;
Menopausal women (with or without hysterectomy) must also meet 1 of the following 3 conditions:
A Non-hysterectomy, menopause ≥ 12 months; B. Menopause > 6 months and < 12 months or premenopausal hysterectomy, follicle stimulating hormone (FSH) > 40 IU/L; C ≥ 6 months since baseline assessment (Day 1) with or without hysterectomy.
- At screening and baseline (Day 1), the subject presented with moderate-severe dyspareunia (dyspareunia) as measured by the Vaginal Atrophy Symptom Questionnaire (VASQ) and self-rated as the most bothersome symptom.
- ≤ 5% superficial cells by vaginal smear at screening and baseline (Day 1).
- Vaginal pH > 5 at Screening and Baseline (Day 1).
- Women (with or without a partner) who currently have sex or other sexual activity (masturbation, etc.) at least once a month, or who have sex or other sexual activity at least once a month in the past, with reduced sexual activity due to excessive pain or vaginal dryness.
- Normal physical examination of the breast and normal mammographic findings (BI-RADS grade 1 or 2) within 9 months prior to the baseline visit (Day 1).
- Normal cervical smear results (including inflammatory changes), regardless of hysterectomy (no abnormal cervical smear in the past 2 years if ASCUS is present, and human papillomavirus (HPV) test negative can be used) within 12 months before the baseline visit (Day 1).
Voluntarily participate in this clinical trial and sign the informed consent form (ICF).
-
Exclusion Criteria:
- Patients with a history of malignant tumor.
- Have active or history of thromboembolic disease (excluding thromboembolic events due to accidents, surgery, immobilization).
- Clinically significant endocrine metabolic disease (e.g., diabetes mellitus) not controlled with medication.
- Use of estrogen injections, estrogen implant sticks, progestogen injections, progestogen implants, androgens, anabolic steroids within 6 months of the screening visit.
- Use oral estrogen, oral progesterone, prasterone (DHEA) or intrauterine progesterone treatment, intravaginal hormonal drugs (ring, cream, gel or tablet), estrogen alone or estrogen/pregnancy within 8 weeks before the screening visit, hormone transdermal drug users.
- Confirmed depression with poor control under standard treatment or history of diagnosed psychiatric disorder.
- Those who have participated in or plan to participate in other drug or device clinical trials during the study period within 1 month prior to the screening visit.
- Laboratory findings suggestive of glutamic-pyruvic transaminase (ALT), glutamic oxaloacetic transaminase (AST) ≥ 2 times the upper limit of normal, or creatinine ≥ 1.5 times the upper limit of normal.
- Grade 2 and higher uterine prolapse (cervix reaching labia minora).
- Transvaginal ultrasound revealed a uterine fibroid ≥ 3 cm in diameter.
- Endometrial thickness ≥ 4 mm by transvaginal ultrasound, or other comprehensive assessment by the investigator with the possibility of endometrial hyperplasia, deterioration.
- Current endometrial polyps.
- Previous endometrial ablation.
- Patients with vulvar lichen sclerosus.
- Patients with unexplained vaginal bleeding.
- Patients who are known to be allergic to the study drug or its ingredients.
- Patients who have participated in other relevant clinical trials of the investigational drug (prasterone vaginal suppositories).
- History of past or present drug or alcohol abuse (14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine).
Subjects who are unable to perform the procedures required by the protocol, or any other subjects who are not suitable for this clinical study judged by the investigator.
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intravaginal prasterone
6.5 mg of Intravaginal prasterone once daily at bedtime with a finger to insert the vaginal suppository into the vagina for a treatment cycle of 12 weeks.
|
6.5 mg of Intravaginal prasterone once daily at bedtime with a finger to insert the vaginal suppository into the vagina for a treatment cycle of 12 weeks.
Other Names:
|
Placebo Comparator: Placebo ovules
Placebo ovules once daily at bedtime with a finger to insert the vaginal suppository into the vagina for a treatment cycle of 12 weeks.
|
Placebo ovules once daily at bedtime with a finger to insert the vaginal suppository into the vagina for a treatment cycle of 12 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The change in the dyspareunia (dyspareunia) severity score at Day 85.
Time Frame: week 12
|
Compared with Day 1, the changes in the dyspareunia (dyspareunia) severity score (by VASQ) at Day 85 (12 weeks) in the two groups of subjects.
|
week 12
|
The change in the vaginal pH at Day 85.
Time Frame: week 12
|
Compared with Day 1, the changes in the vaginal pH changes at Day 85 (12 weeks) in the two groups of subjects.
|
week 12
|
The change in the proportion of parabasal cells at Day 85.
Time Frame: week 12
|
Compared with Day 1, the changes in the proportion of parabasal cells at Day 85 (12 weeks) in the two groups of subjects.
|
week 12
|
The change in the proportion of superficial cells at Day 85.
Time Frame: week 12
|
Compared with Day 1, the changes in the proportion of superficial cells at Day 85 (12 weeks) in the two groups of subjects.
|
week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in vaginal dryness and vaginal irritation/itching severity score at day 85 (12 weeks).
Time Frame: week 12
|
Compared with the baseline period, at day 85 (12 weeks) in both groups: change in vaginal dryness and vaginal irritation/itching severity score by VASQ.
|
week 12
|
Change in Female Sexual Function Index at Day 85 (12 weeks).
Time Frame: week 12
|
Compared with the baseline period, the two groups at Day 85 (12 weeks): change in Female Sexual Function Index (FSFI questionnaire).
|
week 12
|
Effects on DHEA in blood
Time Frame: week 12
|
To test the concentrations of DHEA in blood.
|
week 12
|
Changes in the gynecological vaginal examination.
Time Frame: week 12
|
The changes of total severity score in the vaginal discharge, vaginal epithelial integrity, vaginal epithelial surface thickness, and vaginal color by gynecological vaginal examination.
|
week 12
|
Adverse event.
Time Frame: week 6,week 12
|
The proportion of adverse events.
|
week 6,week 12
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: long Sui, No. 419, Fangxie Road, Huangpu District, Shanghai
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- INT-ZK-2021
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postmenopausal Vulvovaginal Atrophy
-
Peking University People's HospitalChinese Association of Plastics and AestheticsRecruitingPostmenopausal Vulvovaginal AtrophyChina
-
Warner ChilcottCompletedPostmenopausal Vulvovaginal AtrophyUnited States
-
Nathura S.p.AEvidilya S.r.l.Recruiting
-
Koru Health GroupsCompletedVulvovaginal AtrophyTurkey
-
MadorraCompletedVulvovaginal AtrophyAustralia
-
Warner ChilcottCompletedVulvovaginal AtrophyUnited States
-
El. En. SpAStanford University; The Christ HospitalCompletedVulvovaginal AtrophyUnited States
-
PepTonic Medical ABCompletedVulvovaginal AtrophySweden
-
Faculdade de Medicina do ABCCompleted
-
University of MessinaUniversity of Victoria; University of AthensCompletedMenopause | Vulvovaginal Atrophy
Clinical Trials on intravaginal prasterone
-
Pamukkale UniversityCompleted
-
Population CouncilNational Institute of Allergy and Infectious Diseases (NIAID); National Institute... and other collaboratorsCompletedHealthyUnited States, India
-
International Partnership for Microbicides, Inc.Completed
-
University of PittsburghUnited States Agency for International Development (USAID); Oak Crest Institute...RecruitingSafety | AcceptabilityUnited States, South Africa, Zimbabwe
-
University Hospital, Strasbourg, FranceFIZIMEDCompletedStress Urinary IncontinenceFrance
-
University of Sao PauloCompletedElectric Stimulation Therapy | Pelvic Floor | Muscle | ContractionBrazil
-
J3 Bioscience, Inc.Advanced Clinical ResearchCompleted
-
Albert Einstein College of MedicineNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
Universitaire Ziekenhuizen KU LeuvenRecruitingGenitourinary Syndrome of MenopauseBelgium
-
INVO Bioscience, Inc.Ferring PharmaceuticalsSuspended